<DOC>
	<DOC>NCT01126892</DOC>
	<brief_summary>A multicenter, open label study of Nilotinib in CML patients PH + with imatininb resistant in blast crisis, accelerated phase or chronic phase. The main purpose is evaluate the safety and efficacy of Nilotinib.</brief_summary>
	<brief_title>A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Stratum 1: 1. Currently participating in Novartis study CAMN107A2109 2. Written signed and dated informed consent prior to any study procedures being performed Stratum 2: 1. Male or female 2. &gt; 18 years 3. ECOG 0,1,2 4. ASL/ALT &lt;= 2.5 ULN or &lt;= 5.0 ULN 5. Alcaline Phosfatase &lt;= 2.5 ULN 6. Serum Bilirrubin &lt;= 1.5 ULN 7. Serum Creatinine &lt;= 1.5 ULN or creatinine clearance &gt;=50 ml/min / 24 hours 8. Serum Lipase &lt;= 1.5 ULN Stratum 1 and stratum 2: 1. Reduction of the cardiac function 2. Use of Coumadin 3. Other severe medical concurrent conditions 4. Treatment with medications that prolonged the QT interval. 5. Mayor surgery 15 days before the inclusion in the protocol 6. Pregnant women or lactation Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced Disease,</keyword>
	<keyword>Resistance,</keyword>
	<keyword>Intolerance</keyword>
</DOC>